624 related articles for article (PubMed ID: 7620838)
1. Binding of fosphenytoin, phosphate ester pro drug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin.
Lai CM; Moore P; Quon CY
Res Commun Mol Pathol Pharmacol; 1995 Apr; 88(1):51-62. PubMed ID: 7620838
[TBL] [Abstract][Full Text] [Related]
2. Valproic acid: in vitro plasma protein binding and interaction with phenytoin.
Cramer JA; Mattson RH
Ther Drug Monit; 1979; 1(1):105-16. PubMed ID: 121944
[TBL] [Abstract][Full Text] [Related]
3. Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
Joerger M; Huitema AD; Boogerd W; van der Sande JJ; Schellens JH; Beijnen JH
Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):133-40. PubMed ID: 16918714
[TBL] [Abstract][Full Text] [Related]
4. Phenytoin-oxacillin interactions in normal and uremic sera.
Dasgupta A; Sperelakis A; Mason A; Dean R
Pharmacotherapy; 1997; 17(2):375-8. PubMed ID: 9085332
[TBL] [Abstract][Full Text] [Related]
5. Methodologic factors influencing plasma binding of alpha-1-acid glycoprotein-bound and albumin-bound drugs.
Morse DS; Abernethy DR; Greenblatt DJ
Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):535-9. PubMed ID: 3934087
[TBL] [Abstract][Full Text] [Related]
6. Serum protein binding of valproic acid in healthy subjects and in patients with liver disease.
Urien S; Albengres E; Tillement JP
Int J Clin Pharmacol Ther Toxicol; 1981 Jul; 19(7):319-25. PubMed ID: 6790449
[TBL] [Abstract][Full Text] [Related]
7. [Characterization of propofol binding to plasma proteins and possible interactions].
Garrido MJ; Jiménez RM; Rodríguez-Sasiaín JM; Aguirre C; Aguilera L; Calvo R
Rev Esp Anestesiol Reanim; 1994; 41(6):308-12. PubMed ID: 7838996
[TBL] [Abstract][Full Text] [Related]
8. Elevated free fosphenytoin concentrations in uremic sera: uremic toxins hippuric acid and indoxyl sulfate do not account for the impaired protein binding of fosphenytoin.
Dasgupta A; Havlik D
Ther Drug Monit; 1998 Dec; 20(6):658-62. PubMed ID: 9853983
[TBL] [Abstract][Full Text] [Related]
9. Serum protein binding of phenytoin, diazepam and propranolol in chronic renal diseases.
Tiula E; Tallgren LG; Neuvonen PJ
Int J Clin Pharmacol Ther Toxicol; 1987 Oct; 25(10):545-52. PubMed ID: 3429058
[TBL] [Abstract][Full Text] [Related]
10. Serum protein binding of phenytoin, diazepam and propranolol in age-related decrease in renal function.
Tiula E; Elfving S
Ann Clin Res; 1987; 19(3):163-9. PubMed ID: 3674731
[TBL] [Abstract][Full Text] [Related]
11. Effect of heparin or salicylate infusion on serum protein binding and on concentrations of phenytoin in serum, brain and cerebrospinal fluid of rats.
Chou RC; Levy G
J Pharmacol Exp Ther; 1981 Oct; 219(1):42-8. PubMed ID: 7288614
[TBL] [Abstract][Full Text] [Related]
12. Binding of erythromycin base to human plasma proteins.
Prandota J; Tillement JP; d'Athis P; Campos H; Barre J
J Int Med Res; 1980; 8 Suppl 2():1-8. PubMed ID: 7429002
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting serum protein binding of phenytoin, diazepam and propranolol in acute renal diseases.
Tiula E; Haapanen EJ; Neuvonen PJ
Int J Clin Pharmacol Ther Toxicol; 1987 Sep; 25(9):469-75. PubMed ID: 3679617
[TBL] [Abstract][Full Text] [Related]
14. The effects of selected drugs on the in vitro protein binding of repaglinide in human plasma.
Plum A; Müller LK; Jansen JA
Methods Find Exp Clin Pharmacol; 2000 Apr; 22(3):139-43. PubMed ID: 10893694
[TBL] [Abstract][Full Text] [Related]
15. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor.
Kiriyama A; Nishiura T; Ishino M; Yamamoto Y; Ogita I; Kiso Y; Takada K
Biopharm Drug Dispos; 1996 Dec; 17(9):739-51. PubMed ID: 8968527
[TBL] [Abstract][Full Text] [Related]
16. Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands.
Kragh-Hansen U
Mol Pharmacol; 1988 Aug; 34(2):160-71. PubMed ID: 3412320
[TBL] [Abstract][Full Text] [Related]
17. Application of spin labeling to drug assays. II. Determination of the binding of [14C]-phenytoin and spin-labeled phenytoins to albumin and human serum.
Chou D; Polnaszek CF; Yost Y; Leppik IE; Holtzman JL
Mol Pharmacol; 1981 Nov; 20(3):674-80. PubMed ID: 7329409
[No Abstract] [Full Text] [Related]
18. Binding of drugs to human serum albumin. XIV. The theoretical basis for the interaction between phenytoin and valproate.
Kober A; Olsson Y; Sjöholm I
Mol Pharmacol; 1980 Sep; 18(2):237-42. PubMed ID: 6775182
[No Abstract] [Full Text] [Related]
19. Alterations in serum protein binding and pharmacokinetics of l-propranolol in the rat elicited by the presence of an indwelling venous catheter.
Terao N; Shen DD
J Pharmacol Exp Ther; 1983 Nov; 227(2):369-75. PubMed ID: 6631719
[TBL] [Abstract][Full Text] [Related]
20. Factors affecting serum protein binding of cocaine in humans.
Parker RB; Williams CL; Laizure SC; Lima JJ
J Pharmacol Exp Ther; 1995 Nov; 275(2):605-10. PubMed ID: 7473145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
